MP calls for modernisation of fertility laws
Dame Caroline Dinenage has proposed a bill in Parliament to update the dated Human Fertility and Embryology Act 1990.
The bill, titled the Human Fertilisation and Embryology (Regulation) Bill, aims to bring online fertility services and digital concierge providers under regulatory supervision.
This move comes after the sudden closure of Apricity Fertility, an online fertility hub, just before Christmas, leaving hundreds of patients stranded in their treatments.
READ MORE: Life-saving baby care service celebrates ten years of support
Dame Caroline said in the Commons: "This is a classic case of regulation just not keeping pace with modern life.
"It is criminal that organisations that are in the business of making dreams come true can just disappear, along with people's money and their hopes of starting a family."
She also urged ministers to support the bill to protect families.
The bill is backed by 11 MPs from various political parties and is set for a second reading on September 12.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) ('Waldencast'), a global multi-brand beauty and wellness platform, today announced that it has acquired Novaestiq Corp. (Novaestiq), a growth-oriented aesthetic and medical dermatological innovations company, as well as the U.S. rights to the Saypha® line of hyaluronic acid (HA) injectable gels. The strategic acquisition expands Obagi Medical's offerings beyond U.S. medical-grade skincare, a market projected to be $2.2 billion by 2029, into the growing U.S. dermal filler market, projected to reach $2 billion in market size by 2029, effectively doubling its addressable market.1 The move marks a pivotal step in positioning Obagi Medical as an industry leader in integrated skincare and aesthetic solutions. 'We are excited to further diversify Obagi Medical's portfolio of medical-grade skincare with consumer centric, in-office injectable procedures through the introduction of the Obagi Medical Saypha® ChIQ™ and MagIQ™ lines of injectable HA gels,' said Michel Brousset, Co-Founder and CEO of Waldencast. 'Adding proven products into our portfolio increases our addressable market and allows us to deliver solutions for professionals and patients seeking both skincare and aesthetic treatments, all under the trusted Obagi Medical brand.' Obagi Medical's philosophy advocates for a holistic, science-driven approach where potent skincare and professional procedures work in tandem to achieve and maintain optimal skin health and a youthful appearance. These injectable products will play a pivotal role in the evolution of Obagi Medical into an end-to-end, synergistic solution that integrates medical-grade skincare with aesthetic treatments to deliver enhanced outcomes, prolonged results, and greater patient satisfaction. Beyond the two current offerings, the Novaestiq transaction provides access to a future pipeline of novel injectables in North America. Saypha®,2 currently undergoing U.S. Food and Drug Administration (FDA) approval, is recognized globally as a proven, safe and efficacious HA injectable with high levels of patient satisfaction. The new Obagi Medical injectable portfolio is supported by an industry-leading clinical program that reflects the brand's commitment to science-backed innovation. Core pivotal studies are more than twice the size of typical nasolabial fold (NLF) and midface trials and include the highest representation of Fitzpatrick Skin Types I, V, and VI – underscoring Obagi Medical's mission to provide effective solutions for all skin types and tones. Saypha® is distinguished by its proprietary technology delivering advanced HA treatments through a stable 3D matrix designed to provide natural-looking results with optimally balanced gel characteristics. This technology powers a portfolio of clinically proven products that lead in multiple performance categories including high HA content at injection, ideal gel distribution, and consistent injection force and swelling behavior. Saypha®, a product of Croma-Pharma GmbH, is developed and manufactured in Austria and marketed in over 80 countries, leveraging 40 years of expertise in HA-based treatments with more than 110 million syringes produced. This global reach and deep market insight allow for the delivery of trusted, personalized care to patients and professionals worldwide. 'We believe that great results start with great skincare and are perfected with great after care,' said Dr. Suzan Obagi, Chief Medical Director at Obagi Medical. 'By combining Obagi Medical skincare with injectable procedures under the guidance of a qualified professional, patients can achieve more significant, longer-lasting, and natural-looking results. This acquisition also allows our professionals to offer patients more personalized, higher quality and safer products that their customers are looking for.' Obagi Medical's vision is to become the #1 Dermatological Mega Brand uniquely serving all the needs of physicians, patients and consumers globally. It is already the fastest-growing U.S. professional-skincare brand among the top ten in its category.3 This momentum is powered by a three-pronged strategy: anchoring products in dermatological science, introducing breakthrough innovations, and expanding its global reach. Brousset added, 'We are thrilled to introduce this new offering that will strengthen Obagi Medical's market position, drive innovation, and create new growth opportunities in our fast-evolving industry. We see an accelerating global convergence of health, beauty, and aesthetics – an intersection where Obagi Medical is uniquely positioned to lead. We also plan to leverage this acquisition to expand Obagi Medical's footprint.' Transaction DetailsUnder the terms of the definitive agreement relating to the transaction, Waldencast has agreed to acquire Novaestiq in exchange for (1) certain amount of cash payable at closing, (2) certain additional ongoing royalties based on net sales of Saypha® products, and (3) the contingent issuance of Waldencast class A shares (equal to approximately 7% of Waldencast's fully diluted class A shares), based on the receipt of FDA approval relating to the Saypha® products (triggering the issuance of 3,273,000 Waldencast class A shares) and the achievement of cumulative net revenue thresholds of (a) $100 million (triggering the issuance of an additional 3,273,000 Waldencast class A shares) and (b) $200 million (triggering the further issuance of 3,273,000 Waldencast class A shares), respectively, reflecting meaningful long-term commercial targets, with (a) and (b) being earnable until June 20, 2031. The details of the transaction will be summarized in more detail in a Form 6-K that Waldencast will file with the U.S. Securities and Exchange Commission (the 'SEC') following this press release. About WaldencastFounded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand's distinct DNA. The first step in realizing its vision was the business combination with Obagi Medical and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: . About Obagi MedicalObagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,3 Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi is available on the brand's website, 1In preparing for this transaction, Waldencast engaged management consulting services from a reputed global consulting firm. 2Saypha® products are not approved medical devices, and each product has a premarket approval (PMA) application under review by the FDA. 3Among the Top 10 Professional Skin Care Brands in the U.S., according to Kline's 2024 Global Professional Skin Care Series (China, Europe and the U.S.). AdvisorsHolland & Knight LLP is serving as Waldencast's legal advisor, with support from Skadden, Arps, Slate, Meagher & Flom LLP. Experium Capital Advisers is serving as Waldencast's financial advisor. Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the intended benefits of the transaction with Novaestiq, the ability to obtain FDA approval for Saypha®, the contingent issuance of Waldencast class A shares, and the growth strategies of Waldencast, including Obagi Medical and Novaestiq. These forward-looking statements generally are identified by the words 'estimates,' 'projects,' 'expects,' 'anticipates,' 'forecasts,' 'plans,' 'intends,' 'believes,' 'seeks,' 'may,' 'will,' 'would,' 'should,' 'future,' 'propose,' 'target,' 'goal,' 'objective,' 'outlook' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of Waldencast, Obagi Medical and Novaestiq that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, but are not limited to: (i) the inability to recognize the anticipated benefits of the transaction; (ii) the inability to obtain FDA approval for one or both of the Saypha® products; (iii) the general impact of geopolitical events, including the impact of current wars, conflicts and other hostilities; (iv) the overall economic and market conditions, sales forecasts and other information about Waldencast's possible or assumed future results of operations or our performance; (v) changes in general economic conditions; (vi) the impact of any international trade or foreign exchange restrictions, the imposition of new or increased tariffs, foreign currency exchange fluctuations; (vii) that the price of Waldencast's securities may be volatile due to a variety of factors, including Waldencast's, Obagi Medical's or Novaestiq's inability to implement their business plans; and (viii) the ability to implement Waldencast's strategic initiatives and continue to innovate Obagi Medical's existing products and anticipate and respond to market trends and changes in consumer preferences. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of Waldencast's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on March 20, 2025, or in other documents that may be filed or furnished by Waldencast from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Waldencast assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Contacts InvestorsICRinvestors@ MediaICRwaldencast@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Healey signs agreement paving way for export of Typhoon jets to Turkey
The Defence Secretary has signed an agreement paving the way for the export of Typhoon fighter jets to Turkey. John Healey and Turkish counterpart Yaşar Guler signed a memorandum of understanding at the International Defence Industry Fair in Istanbul. It comes after the German government reportedly cleared the path for the delivery of 40 Typhoon Eurofighter jets to Turkey. 'Today's agreement is a big step towards Turkiye buying UK Typhoon fighter jets,' Mr Healey said. 'It shows this government's determination to secure new defence deals, building on our relationships abroad to deliver for British working people. 'Equipping Turkiye with Typhoons would strengthen Nato's collective defence, and boost both our countries' industrial bases by securing thousands of skilled jobs across the UK for years to come.' More than a third of each aircraft will be manufactured in the UK, with final assembly taking place at the BAE Systems site in Lancashire. The Typhoon jet programme is a partnership with Germany, Spain and Italy. Germany's security council has signed off on a Turkish request to buy the jets, which will use German parts, Der Spiegel reported, and has informed Turkish and Greek leaders of the decision. The programme supports 20,000 jobs in the UK. The RAF's own fleet of Typhoons is being upgraded over the next 15 years.
Yahoo
an hour ago
- Yahoo
Iberdrola Starts €5 Billion Share Sale for Grid Investment
(Bloomberg) -- Iberdrola started a €5 billion ($5.9 billion) capital increase, the biggest share sale in Europe so far this year, to bolster investments in power networks and further its US and UK expansion. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US Why the Federal Reserve's Building Renovation Costs $2.5 Billion Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Milan Corruption Probe Casts Shadow Over Property Boom How San Jose's Mayor Is Working to Build an AI Capital The indicative price guidance for the Spanish energy giant's accelerated bookbuild was €15.10 per share to market, according to terms seen by Bloomberg. Iberdrola's closing price was €15.895 on Tuesday, bringing the stock's gains to 20% this year. Indicative investor interest exceeds of the size of the offer, with the company's shares suspended in early Madrid trading. Iberdrola is one of a handful of companies cashing in on the unprecedented demand to build out power grids as countries work to decarbonize and meet rising electricity demand. The company expects to invest some €55 billion globally over the next six years, an increase of 75% compared with the previous six years. The Spanish utility will maintain its focus on the US and UK, saying tariff frameworks for transmission and distribution activities in the two markets represent 'an unprecedented investment opportunity.' By contrast, Iberdrola sees little incentive to invest in its home market of Spain. Antitrust regulator CNMC has proposed increasing network returns to 6.46%, but that remains below the level of other European countries. That proposal gives 'a clearly negative signal to the market,' Iberdrola Chairman Ignacio Galan said Wednesday on an earnings call. The reliability of the Spanish power network has also been questioned in the wake of the nationwide blackout that left millions of people without electricity at the end of April. Iberdrola expects its regulated asset base to triple to more than €90 billion in 2031 from the level in 2020. While investments will grow almost fourfold in the UK and near double in the US, the company's Spanish assets are projected to shrink by 10% to €3.5 billion. --With assistance from Bre Bradham and William Mathis. (Updates with details throughout) Elon Musk's Empire Is Creaking Under the Strain of Elon Musk Burning Man Is Burning Through Cash A Rebel Army Is Building a Rare-Earth Empire on China's Border Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot How Starbucks' CEO Plans to Tame the Rush-Hour Free-for-All ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
